Cardiac Function and Heart Failure p=0.0006). Differences were already observed after several months and were maintained over time. Changes in blood pressure from baseline, measured at 4 months treatment, were comparable (p>0.6) between C and M in patients dying from stroke. Stroke or myocardial infarction, combined, occurred in 130 C versus 168 M patients (HR 0.75, CI 0.60-0.95, p=0.02) Conclusion: C reduced the major components of CV death in HF, sudden and HF death, more than metoprolol. In addition, carvedilol reduced stroke deaths and myocardial infarction compared to metoprolol. These results suggest a protective effect of C against major vascular events. 9:00 a.m.
Background: The objective of treating most patients (pts) with heart failure is to improve or maintain well-being and to delay death. However, the importance of well-being as a treatment outcome is often forgotten in large clinical trials. Both survival and quality of life (QoL) need to be considered at the same time to assess the true effect of treatment. Treatments that improve survival are likely to have their greatest effect in higher-risk pts. Accordingly, average symptom scores may improve with less effective treatment because sicker pts with more advanced disease die selectively. Adjusting symptoms and QoL for time alive, hospitalization and need for intensified therapy can compensate for such anomalies and better describe the pts experience of disease or 'Patient Journey'. Methods: 3029 pts with left ventricular systolic dysfunction and NYHA class II-IV heart failure were randomised to metoprolol (M) (50mg bd) or carvedilol (C) (25mg bd) and followed for a median of 58 months. Pts were reviewed every 4 months at which time heart failure symptoms and 'well-being' were recorded using a simple 5-point scale. The dates of hospitalizations and death were reported. Results: Baseline NYHA class was 2.6 and improved by 4 months (-0.30+0.59 in C, -0.28+0.57 in M) and plateauing around 2 years (-0.42+0.66 in C, -0.39+0.67 in M). Symptoms scores for breathlessness, fatigue and 'well-being' paralleled these changes. C reduced mortality (hazard ratio 0.83, 95% CI 0.74-0.93, p=0.0017) and prolonged median life expectancy by 1.4 years. Although the difference in survival led to different periods of risk for hospitalization, hospital days/patient were similar (25.6+45 in C, 24.8+42 days in M). Pts on C reported feeling 'good' or 'very good' for 48.7% of study days over the first 4 years versus 45.3% on M (p=0.0118), and 60.3% versus 56.9% were in NYHA class I/II, respectively (p=0.0192). This represents an average of 51 days of greater well-being per patient on C versus M over 4 years in addition to the benefit on survival. Data on health-utility related life-years will be presented. Conclusion: Compared to metoprolol, carvedilol improves symptoms as well as survival in patients with heart failure. 9:30 a.m.
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Candesartan Improves Functional Class Across BACKGROUND Previous studies have shown that levosimendan, a novel calcium sensitiser, is associated with better long-term prognosis as compared to dobutamin in patients with low output heart failure. However, a parallel group assigned to placebo was not included in these studies. METHODS A total of 227 patients with decompansated low output chronic heart failure (LVEF<35%) were recruited into a multicentre, randomised, double-blind, double-dummy, placebo-control parallel-group trial. Levosimedan, dobutamin, or placebo was infused intavenously for 24 h. The composite of death or rehospitalization due to heart failure deterioration during the follow-up, was the primary endpoint.. RESULTS 74, 76 and 77 patients were assigned to levosimendan, dobutamine and placebo respectively. By 6-month the primary endpoint was achieved in 30.6%, 52.7% and 48.1% of the patients in levosimendan, dobutamine and placebo group respectively (P=0.01) (Fig 1) .CONCLUSIONS Levosimedan significantly improves longterm prognosis in patients with decompansated low-output heart failure, as compared to either dobutamine or placebo. 
